Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786967 · ClinicalTrials.gov registry record · Phase 3
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
A Phase 3 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT01786967 is a Phase 3 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 61 participants.
The verdict
NCT01786967, a Phase 3 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
Urge urinary incontinence, characterized by unpredictable and embarrassing large volume urine leakage, is a major health issue for elderly women, as it is incredibly common and significantly impairs quality of life. Although anticholinergic medications are the most common therapy, the investigators are unable to predict an individual's response to a particular drug in terms of both effectiveness and side effects. Through genetic evaluation, the investigators have the potential to personalize and optimize drug therapy for millions of elderly women suffering from urge incontinence.
Interventions
- DRUG Fesoterodine Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786967
The ClinicalTrials.gov registry entry for NCT01786967 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fesoterodine Fumarate is the first listed.
NCT01786967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786967 about?
NCT01786967 is a clinical study titled "Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)". Urge urinary incontinence, characterized by unpredictable and embarrassing large volume urine leakage, is a major health issue for elderly women, as it is incredibly common and significantly impairs quality of life. Although anticholinergic medications are the most common therapy, the investigators ...
What is the current status of trial NCT01786967?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2012-09. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT01786967?
The interventions under investigation include: Fesoterodine Fumarate (DRUG).
Who is sponsoring clinical trial NCT01786967?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.